statistiche ricercatore

GROSSI, FRANCESCO

Distribuzione geografica

Continente	#
NA - Nord America	8.626
EU - Europa	5.513
AS - Asia	4.752
SA - Sud America	629
Continente sconosciuto - Info sul continente non disponibili	543
AF - Africa	89
OC - Oceania	7
Totale	20.159

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	8.388
IT - Italia	3.479
SG - Singapore	2.143
CN - Cina	1.023
HK - Hong Kong	796
IE - Irlanda	575
BR - Brasile	510
VN - Vietnam	352
GB - Regno Unito	304
RU - Federazione Russa	247
FR - Francia	243
SE - Svezia	207
DE - Germania	158
FI - Finlandia	109
CA - Canada	101
IN - India	82
BD - Bangladesh	78
MX - Messico	75
JP - Giappone	42
IQ - Iraq	39
AR - Argentina	37
PL - Polonia	35
TR - Turchia	33
UA - Ucraina	31
ZA - Sudafrica	28
AT - Austria	26
NL - Olanda	26
ES - Italia	21
EC - Ecuador	20
SA - Arabia Saudita	20
ID - Indonesia	18
PK - Pakistan	18
CO - Colombia	17
PH - Filippine	16
VE - Venezuela	16
UZ - Uzbekistan	15
CR - Costa Rica	12
JM - Giamaica	11
JO - Giordania	11
TT - Trinidad e Tobago	11
BE - Belgio	10
DZ - Algeria	10
KE - Kenya	10
TH - Thailandia	10
LT - Lituania	9
TN - Tunisia	9
CL - Cile	8
EG - Egitto	8
MA - Marocco	8
PY - Paraguay	8
AE - Emirati Arabi Uniti	7
NG - Nigeria	7
MY - Malesia	6
UY - Uruguay	6
AU - Australia	5
EE - Estonia	5
NP - Nepal	5
OM - Oman	5
PE - Perù	5
AL - Albania	4
EU - Europa	4
KZ - Kazakistan	4
MD - Moldavia	4
NI - Nicaragua	4
PA - Panama	4
AZ - Azerbaigian	3
BZ - Belize	3
CH - Svizzera	3
ET - Etiopia	3
GT - Guatemala	3
HN - Honduras	3
IL - Israele	3
KG - Kirghizistan	3
PS - Palestinian Territory	3
PT - Portogallo	3
AO - Angola	2
BB - Barbados	2
BG - Bulgaria	2
BO - Bolivia	2
DO - Repubblica Dominicana	2
GD - Grenada	2
GE - Georgia	2
GR - Grecia	2
LB - Libano	2
NO - Norvegia	2
QA - Qatar	2
RO - Romania	2
RS - Serbia	2
SV - El Salvador	2
SY - Repubblica araba siriana	2
TW - Taiwan	2
BH - Bahrain	1
BS - Bahamas	1
BY - Bielorussia	1
CG - Congo	1
CY - Cipro	1
CZ - Repubblica Ceca	1
DK - Danimarca	1
DM - Dominica	1
GA - Gabon	1
Totale	19.609

Salva come PNG Salva come JPEG

Città	#
Milan	2.468
San Jose	1.709
Singapore	1.121
Hong Kong	781
Council Bluffs	719
Ashburn	656
Dublin	575
Dallas	498
Princeton	435
The Dalles	305
Fairfield	300
Boardman	267
Beijing	251
Rome	235
Lauterbourg	218
Wilmington	200
Chicago	191
Nyköping	160
Santa Clara	140
Chandler	131
Ho Chi Minh City	131
Los Angeles	118
San Diego	117
London	113
Woodbridge	113
Seattle	102
Houston	94
Hanoi	88
Ogden	86
Helsinki	84
New York	84
Cambridge	75
Ann Arbor	56
São Paulo	53
Mexico City	46
Como	45
Orem	37
Munich	34
Warsaw	32
Tokyo	31
Brooklyn	29
Guangzhou	29
San Francisco	29
Frankfurt am Main	28
Salt Lake City	28
Naples	27
Denver	25
Nuremberg	24
Atlanta	23
Pune	23
Norwalk	22
Shanghai	22
Toronto	21
Montreal	20
Tampa	20
Da Nang	19
Hangzhou	19
Las Vegas	19
Chennai	18
Chiswick	18
Baghdad	17
Phoenix	17
Catania	16
Kilburn	16
Redmond	16
Rio de Janeiro	16
Stockholm	16
Washington	16
Boston	15
Buffalo	15
Jacksonville	15
Turku	15
Vienna	15
Johannesburg	14
Miami	14
Shenzhen	14
Zhengzhou	14
Amsterdam	12
Tashkent	12
Tianjin	12
Turin	12
Belo Horizonte	11
Fair Lawn	11
Manchester	11
Poplar	11
Wuhan	11
Amman	10
Charlotte	10
Curitiba	10
Genoa	10
Brasília	9
Brussels	9
Dhaka	9
Düsseldorf	9
Elk Grove Village	9
Falkenstein	9
Haiphong	9
San José	9
Ankara	8
Biên Hòa	8
Totale	13.854

Salva come PNG Salva come JPEG

Nome	#
Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines.	184
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin	184
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)	148
Afatinib for the treatment of non-small cell lung cancer	145
Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis	141
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial	139
Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis	135
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer	132
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy	128
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study	124
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation	123
A review of clinical practice guidelines and treatment recommendations for cancer care in the COVID-19 pandemic	122
DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer	119
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy	119
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study	117
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial	117
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer	116
Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines	114
Afatinib for the treatment of advanced non-small-cell lung cancer	113
Novel treatment strategies for early-stage lung cancer: The oncologist’s perspective	113
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation	110
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019)	109
Advances in treatment of mesothelioma	106
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial	105
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial	103
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes	102
Hematopoietic growth factors in lung cancer	102
Alternating bolus and continuous infusion 5-fluorouracil: A strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients	102
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial	101
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low cost chemotherapy for advanced colorectal cancer	100
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer	100
Liquid biopsy in non-small cell lung cancer: highlights and challenges	100
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells	97
Vinflunine for the treatment of non-small cell lung cancer	97
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy	97
Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib	97
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743	96
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)	96
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer	96
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer	96
Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study	95
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients	94
Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects	94
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes from the Phase 3 KEYNOTE-189 Study	94
Exosomes: a new horizon in lung cancer	94
Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers	94
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial	93
Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy	93
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors	93
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine	92
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A randomized study	91
Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial	91
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis	90
Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice?	90
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy	90
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer	90
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)	89
Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification	88
The clinical management of early and advanced colorectal cancer	88
Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer	88
Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer	88
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds	88
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study	87
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab	87
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study	87
Oral Vinorelbine Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-Line Treatment for Patients with Advanced non- Squamous non- Small Cell Lung Cancer: a Cost Minimization Analysis in Twelve European Countries	87
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib	87
Association of steroids use with survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis	87
Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers	86
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study	86
Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells	86
Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries	86
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?	86
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases	85
Systemic drug therapy of malignant pleural mesothelioma.	85
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition	85
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG	85
IDH signalling pathway in cholangiocarcinoma: From biological rationale to therapeutic targeting	85
Triage process for the assessment of coronavirus disease 2019-positive patients with cancer: The ONCOVID prospective study	85
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial	84
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients	84
Ramucirumab: preclinical research and clinical development	84
IL-12 Can Target Human Lung Adenocarcinoma Cells and Normal Bronchial Epithelial Cells Surrounding Tumor Lesions	84
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer	84
Targeting kras in solid tumors: Current challenges and future opportunities of novel kras inhibitors	84
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study	84
NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer	83
Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy	83
Impact of bmi on survival outcomes of immunotherapy in solid tumors: A systematic review	83
Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma	83
Looking for results in non-small-cell lung cancer: is bio-chemotherapy the right answer?	82
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy	82
Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?	82
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy	82
Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer	82
Tag-based next generation sequencing: A feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients	82
Trastuzumab deruxtecan: Changing the destiny of her2 expressing solid tumors	82
COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: A case report	82
COVID-19 vaccination in patients with classic Kaposi’s sarcoma	82
Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?	81
Totale	9.853

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	148.236
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	148.236

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	1.827	0	0	0	0	430	190	192	151	232	186	105	341
2022/2023	1.155	225	49	70	40	78	310	4	69	84	176	16	34
2023/2024	3.882	483	689	646	787	905	116	26	52	146	12	3	17
2024/2025	3.119	17	29	584	41	37	221	101	99	499	220	208	1.063
2025/2026	8.048	393	647	495	975	549	327	1.902	513	1.055	566	327	299
2026/2027	1.950	190	426	979	355	0	0	0	0	0	0	0	0
Totale													20.159